(Q36409512)

14 August 2017

1 reference

title

Telbivudine: a novel nucleoside analog for chronic hepatitis B. (English)

1 reference

14 August 2017

1 reference

Jiwon W Kim

1

1 reference

14 August 2017

Susie H Park

series ordinal

2

1 reference

14 August 2017

Stan G Louie

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

28 February 2006

1 reference

Annals of Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

40

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

472-478

1 reference

Hepatitis B virus infection--natural history and clinical consequences

14 August 2017

cites work

1 reference

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

21 January 2018

1 reference

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

Lamivudine treatment for acute severe hepatitis B: a pilot study

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

Viral dynamics in chronic hepatitis B patients during lamivudine therapy

21 January 2018

1 reference

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily

21 January 2018

1 reference

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro

21 January 2018

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G027

1 reference

14 August 2017

1 reference